Janssen ventures into antithrombin antibody-based drugs

Candace Stuart | | Cardiovascular Business | Heart Rhythm

Janssen Pharmaceuticals acquired a university spinout company that develops an antithrombin antibody, adding another potential therapy to its portfolio.

Janssen makes the novel oral anticoagulant rivaroxaban (Xarelto), a factor Xa inhibitor that received FDA approved in 2012 as a treatment for deep vein thrombosis and pulmonary embolism and to reduce the risk of recurrences. The drug previously was cleared in the U.S. to reduce the risk of stroke in patients with nonvalvular atrial fibrillation.

Janssen purchased XO1 Limited, a biopharmaceutical company that developed the antithrombin antibody ichorcumab. Researchers from Addenbrooke Hospital and Cambridge University in the U.K. invented and designed the drug, which is a recombinant human antibody that targets thrombin. Unlike other anticoagulants, ichorcumab is said to provide anticoagulation properties yet not increase the risk of bleeding.

Neither Janssen nor X01 disclosed financial terms for the deal. Johnson & Johnson Innovation in London facilitated in agreement. Janssen Pharmaceuticals is a Johnson & Johnson company.

Candace Stuart, Contributor

Related Content

Eko Health’s AI platform for digital stethoscopes granted new CPT code
Predicting sudden cardiac death after a heart attack may be impossible—for now
Concomitant ablation surgery during heart operations boosts long-term survival
Johnson & Johnson MedTech gains FDA approval for Varipulse PFA system
Boston Scientific agrees to acquire AFib ablation company
Heart Rhythm Society launches new group focused on EP advocacy

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Design by Adaptive Theme
Trimed Popup
Trimed Popup